The AGPS degradation-induced enrichment of membrane polyunsaturated fatty acids (PUFAs) synergizes with ML210-mediated GPX4 inhibition, significantly enhancing ferroptosis in prostate cancer cells [64]. Here, GPX4 is linked to prostate carcinoma.